Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for SymBio Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
TSE:4582'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.43 Med: 0.38 Max: 4.44
Current: -1.43
During the past 13 years, the highest Debt-to-Equity Ratio of SymBio Pharmaceuticals was 4.44. The lowest was -1.43. And the median was 0.38.
TSE:4582's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.28
vs TSE:4582: -1.43
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
SymBio Pharmaceuticals Debt-to-Equity Related Terms
SymBio Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for SymBio Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SymBio Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where SymBio Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SymBio Pharmaceuticals (TSE:4582) has a Debt-to-Equity of -1.43 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SymBio Pharmaceuticals and its competitors. According to the industry distribution chart, SymBio Pharmaceuticals ranks #999999 out of 810 companies in the Drug Manufacturers industry.
Is SymBio Pharmaceuticals' Debt-to-Equity too high?
SymBio Pharmaceuticals' current Debt-to-Equity is -1.43. Based on the distribution chart, SymBio Pharmaceuticals ranks #999999 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SymBio Pharmaceuticals has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SymBio Pharmaceuticals ranks #999999 out of 810 companies for Debt-to-Equity. This places SymBio Pharmaceuticals in the lower half of its industry. The industry median Debt-to-Equity is 0.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SymBio Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SymBio Pharmaceuticals's current Debt-to-Equity is -1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Significantly Overvalued. The stock's GF Value™ is 円43.31, compared to a current price of 円61.00 — trading 40.8% above its estimated fair value. The current Debt-to-Equity is -1.43. SymBio Pharmaceuticals' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current Debt-to-Equity is -1.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?
Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued.
The current stock price of 円61.00 is trading 40.8% above its estimated GF Value™ of 円43.31.
GuruFocus considers SymBio Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for TSE:4582:
Debt-to-Equity: -1.43
GF Value™: 円43.31 vs. price of 円61.00 (40.8% above fair value)
No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
31GF Score
Get the complete analysis for TSE:4582
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4582 has been successfully added to your 
